Evaluation of recombinant cytochrome p450 enzymes as an in vitro system for metabolic clearance predictions

Drug Metabolism and Disposition

Volumn 37, Issue 5, 2009, Pages 1025-1034

  Stringer, Rowan A ^a   Strain Damerell, Claire ^a   Nicklin, Paul ^a   Houston, J Brian ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BUFURALOL; BUPIVACAINE; BUPRENORPHINE; BUSPIRONE; CHLORPHENIRAMINE; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DICLOFENAC; DILTIAZEM; DOMPERIDONE; FENTANYL; FLUPHENAZINE; GLIMEPIRIDE; HALOPERIDOL; IMIPRAMINE; KETAMINE; LIDOCAINE; MEPHENYTOIN; MIDAZOLAM; PHENACETIN; RECOMBINANT CYTOCHROME P450; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

ALGORITHMS; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; FORECASTING; HUMANS; ISOENZYMES; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; RECOMBINANT PROTEINS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 66449122160     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.024810     Document Type: Article

References (35)

1. Becquemont L, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P, and Beaune P (1998) Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics 8:101-108.
2. Belloc C, Baird S, Cosme J, Lecoeur S, Gautier JC, Challine D, de Waziers I, Flinois JP, and Beaune PH (1996) Human cytochromes P450 expressed in Escherichia coli: production of specific antibodies. Toxicology 106:207-219.
3. Boxenbaum H (1980) Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 8:165-176.
4. Brown HS, Griffin M, and Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35:293-301.
5. Clarke SE (1998) In vitro assessment of human cytochrome P450. Xenobiotica 28:1167-1202.
6. Crespi CL (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:179-235.
7. Galetin A, Brown C, Hallifax D, Ito K, and Houston JB (2004) Utility of recombinant enzym kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metab Dispos 32:1411-1420.
8. Gonzalez FJ and Korzekwa KR (1995) Cytochrome P450 expression systems. Annu Rev Pharmacol Toxicol 35:369-390.
9. Guengerich FP and Turvy CG (1991) Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immu- nochemical analysis of surgical liver samples. J Pharmacol Exp Ther 256:1189-1194.
10. HakoozN, ItoK, RawdenH, Gill H, Lemmers L, Boobis AR, Edwards RJ, CarlileDJ, LakeBG, and Houston JB (2006) Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm Res 23:533-539.
11. Hallifax D and Houston JB (2006) Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34:724-726; author reply 727.
12. Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2006) Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 36:473-497.
13. ImaokaS, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, and FunaeY (1996) Multiple forms of human P450 expressed in Saccharomyces cerevisiae: systematic characterization and comparison with those of the rat. Biochem Pharmacol 51:1041-1050.
14. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, and Shimada T (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and 5"-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7:103-113.
15. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112.
16. James LP, Mayeux PR, and Hinson JA (2003) Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 31:1499-1506.
17. Johnson TN, Rostami-Hodjegan A, and Tucker GT (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 45:931-956.
18. Khan KK, He YQ, Domanski TL, and Halpert JR (2002) Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61:495-506.
19. LaskerJM, WesterMR, AramsombatdeeE, andRaucy JL (1998) CharacterizationofCYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353:16-28.
20. Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, and Gaedigk A (2002) Character- izationofcytochromeP4502D6.1 (CYP2D6.1), CYP2D6.2, andCYP2D6.17activitiestoward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab Dispos 30:595-601.
21. Margolis JM and Obach RS (2003) Impact of nonspecific binding to microsomes and phospho- lipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 31:606-611.
22. Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, and Yokoi T (1999) Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 27:1381-1391.
23. Nakajima M, Tane K, Nakamura S, Shimada N, Yamazaki H, and Yokoi T (2002) Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression of NADPH-cytochrome P450 reductase and cytochrome b5 and the differences in marker activities. J Pharm Sci 91:952-963.
24. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
25. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
26. Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2004) Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151-178.
27. Riley RJ, McGinnity DF, and Austin RP (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311.
28. Sheiner LB and Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512.
29. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
30. Soars MG, Gelboin HV, Krausz KW, and Riley RJ (2003) A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. Br J Clin Pharmacol 55:175-181.
31. Venkatakrishnan K, Von Moltke LL, and Greenblatt DJ (2001) Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179.
32. Stringer R, Nicklin PL, and Houston JB (2008) Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. Xenobiotica 38:1313-1329.
33. Venkatakrishnan K, von Moltke LL, Obach RS, and Greenblatt DJ (2000) Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. J Pharmacol Exp Ther 293:343-350.
34. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660.
35. Wester MR, Lasker JM, Johnson EF, and Raucy JL (2000) CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos 28:354-359.